Investors
Aug 13, 2026
Taipei, Taiwan, 13 Aug 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its financial results for the first half and second quarter ended 30 June 2026, se...
Historical News
All Years
All Category
315 Results
Lotus Pharmaceutical Reports Record Revenue in First Half 2026 and Improved Second-Quarter Profitability
Investors
Aug 10, 2026
Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representi...
.jpg)
ESG
Jul 29, 2026
Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that ...
Business
Jul 15, 2026
Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that the United States Food and Drug Administration ("US FDA") has accepted for substantive re...
Business
Jul 15, 2026
Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the first hospital formulary listing and initial commercial shipment of Bostin...
Investors
Jul 13, 2026
Taipei, Taiwan, 13 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for June 2026 of NT$3,399 million, representing...
Business
Jul 7, 2026
Taipei, Taiwan, and Seoul, South Korea, 7 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary Alvogen Korea has succ...
Business
Jul 7, 2026
Taipei, Taiwan, and Seoul, South Korea, 7 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary Alvogen Korea has comm...
Business
Jul 2, 2026
Seoul, South Korea, and Shanghai, China, 2 July 2026 — Alvogen Korea Co., Ltd., ("Alvogen Korea") a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), and Shanghai Henlius Biotech (“Henlius”, Ho...
